India’s ₹1.5 lakh crore functional food market grew 18% in FY25, driven by rising disposable incomes and health consciousness. On March 15, 2026, Mumbai-based start-up NutriVibe Foods launched ‘LoveBite Crunch’—a ₹499 jar of papad-sized chips packed with 10g plant protein per 30g serving. But Mumbai-based clinical nutritionist Priya Shah says, * “There’s no data proving chips reduce muscle soreness unless you’re already protein-deficient.” And she’s blunt: “The ₹22,000 crore Ayurvedic functional food segment in India operates on tradition, not trials.”
Across Delhi’s Khan Market on April 1, 2026, a small kiosk sold ‘KamaSutra Chocolate’ priced at ₹350 for a 50g slab infused with maca root, ashwagandha, and ginseng. Retailer Rajesh Verma said, “We sold 5,000 units in March alone. Customers keep asking if it ‘works’—but who’s testing it?” A 2025 study by AIIMS-Bhopal found maca root supplements caused liver enzyme spikes in 8% of healthy volunteers after 90 days of 3g daily intake. The study, published in the Indian Journal of Medical Research on September 12, 2025, noted, “No long-term safety data exists for maca in Indian populations.”
Probiotic drinks are another battleground. On January 20, 2026, Delhi-based GoodGut launched ‘ImmunityShot’ at ₹22 per 100ml bottle, claiming 10 billion CFU per serve. Delhi’s Max Super Specialty Hospital’s Dr. Anil Mehta, head of gastroenterology, called the claim “plausible but unverified.” He says, “We need locally conducted trials. A 2024 Cochrane review of 33 trials found only three used Indian strains. And none measured actual immunity outcomes like infection rates.”
Ayurvedic functional foods ride on FSSAI’s AYUSH-approved categories, but enforcement lags. In January 2026, FSSAI raided 18 Delhi stores selling ‘immunoboost laddoos’ under the Ayurveda Aahar category. Tests showed batches of one brand contained 40% more vitamin C than labelled. FSSAI’s Ayurveda cell head, Dr. Alok Sharma, told reporters on February 5, 2026, that “34% of Ayurvedic functional foods fail label compliance tests.” The regulator warned traders of ₹1 lakh fines but hasn’t revoked any approvals yet.
Clinicians in India point to another gap: dosage inconsistency. Hyderabad-based Dr. Kavita Patel specialises in sports nutrition. She told *Insurance India*, “I prescribed a client a branded protein chip for recovery post marathons. He ate two packets, thinking more is better. Labs showed his urea levels spiked to 60 mg/dl—near nephrotoxic range. The pack had 500mg BCAA, far above WHO’s 150mg recommendation for athletes.” Official WHO guidelines, updated December 2024, cap supplementary BCAA at 15-20g daily for adults. Dr. Patel now insists clients log intake; “They think snacks are safe because ‘functional’ sounds official.”
For diabetics, 2026 brought a new wave: glucose-control chips. Chennai’s GlycoBalance Foods launched ‘SugarDefy’ chips on February 14, 2026, priced at ₹249 for 100g. Each chip lists ‘2g resistant starch’. But Bengaluru-based endocrinologist Dr. Rajeev Menon found the claim overstated. He reviewed 36 batches in his clinic and told *Insurance India*, “Only 7 batches contained ≥2g resistant starch per 30g serving. The rest had 0.8-1.2g. It’s labelling fraud.”
Regulatory scrutiny is lagging sales. On March 28, 2026, a parliamentary panel chaired by BJP MP Naresh Gujjar recommended “mandatory pre-market trials for functional foods making health claims.” The 10-member panel, after a six-month review, said, “The ₹1.5 lakh crore market operates like the Wild West.” The committee suggested linking FSSAI approvals to NABL-accredited labs—but did not set a timeline.
Market insiders see opportunity. ITC’s Foods Division launched ‘Sunfeast Protein Plus’ biscuits on January 10, 2026, claiming 12g protein per 60g pack. A company spokesperson said, “We invested ₹45 crore in protein isolation tech. Clinical studies on 200 urban adults showed 15% better satiety scores vs regular biscuits.” ITC hasn’t published the full study but shared a two-page summary with *Insurance India*. Meanwhile, older staples like horlicks plus atta remain ₹100 cheaper per kg despite lower protein density.
Health insurance seniors face another worry. A March 2026 report by ICICI Lombard found 12% of claims linked to “over-supplementation.” Dr. Vikram Aditya, medical director at the insurer, said, “Claims for kidney stones rose 23% in policyholders buying unregulated protein supplements online.” He blames “label inaccuracies and unproven dosing.”
Clinicians urge caution but concede demand won’t drop. Delhi endocrinologist Dr. Menon says, “People want quick fixes like chips that ‘build muscle’ or ‘boost libido’ because gym culture is booming and sexual wellness ads are relentless.” He notes Google searches for “sex chocolate India” surged 600% in Q1 2026 vs Q1 2025.
With no single regulator covering efficacy, India’s functional food boom remains a gamble. Until trials under FSSAI’s proposed “health claim verification” portal go live—expected in Q4 2026—consumers will rely on word of mouth. And word of mouth is the weakest science of all.
